Collen A, Smorenburg S M, Peters E, Lupu F, Koolwijk P, Van Noorden C, van Hinsbergh V W
Gaubius Laboratory TNO-PG, Leiden, The Netherlands.
Cancer Res. 2000 Nov 1;60(21):6196-200.
Cancer patients treated for venous thromboembolism with low molecular weight heparin (LMWH) have a better survival rate than patients treated with unfractionated heparin (UFH). Because fibrin-associated angiogenesis is an important determinant in the progression and metastasis of many solid tumors, the effects of heparins on in vitro angiogenesis were investigated. Both UFH and LMWH inhibited bFGF-induced proliferation of human microvascular endothelial cells (hMVECs) to the same the extent (36-60%). VEGF165-induced proliferation was inhibited to a to a lesser extent (19-33%). Turbidity measurements and electron microscopy showed that the presence of LMWH during polymerization of the fibrin matrix led to a more transparent rigid network with thin fibrin bundles, whereas the presence of UFH resulted in a more opaque more porous network with thick fibrin fibers. We used a human in vitro angiogenesis model, which consisted of hMVECs seeded on top of a fibrin matrix, and stimulated the cells with basic fibroblast growth factor plus tumor necrosis factor a to induce capillary-like tubular structures. The formation of capillary-like tubular structures was retarded with matrices polymerized in the presence of LMWH (46% inhibition compared with a control matrix for both 1.5 and 10 units/ml LMWH), whereas matrices polymerized in the presence of UFH facilitated tubular structure formation (72 and 36% stimulation compared with a control matrix for 1.5 and 10 units/ml UFH, respectively). Similar results were obtained for cells stimulated with vascular endothelial growth factor plus tumor necrosis factor alpha. These data demonstrate the inhibitory effect of heparins on proliferation of hMVECs and provide a novel mechanism by which LMWH may affect tumor progression, namely reduced ingrowth of microvascular structures in a fibrinous stroma matrix by rendering it less permissive for invasion.
与接受普通肝素(UFH)治疗的癌症患者相比,接受低分子量肝素(LMWH)治疗静脉血栓栓塞的癌症患者生存率更高。由于纤维蛋白相关的血管生成是许多实体瘤进展和转移的重要决定因素,因此研究了肝素对体外血管生成的影响。UFH和LMWH对碱性成纤维细胞生长因子(bFGF)诱导的人微血管内皮细胞(hMVECs)增殖的抑制程度相同(36%-60%)。对血管内皮生长因子165(VEGF165)诱导的增殖的抑制程度较小(19%-33%)。比浊测量和电子显微镜显示,在纤维蛋白基质聚合过程中LMWH的存在导致形成更透明的刚性网络,纤维蛋白束较细,而UFH的存在导致形成更不透明、孔隙更多的网络,纤维蛋白纤维较粗。我们使用了一种人体外血管生成模型,该模型由接种在纤维蛋白基质上的hMVECs组成,并用碱性成纤维细胞生长因子加肿瘤坏死因子α刺激细胞以诱导毛细血管样管状结构形成。在LMWH存在下聚合的基质使毛细血管样管状结构的形成受到阻碍(1.5和10单位/ml LMWH时与对照基质相比抑制率均为46%),而在UFH存在下聚合的基质促进管状结构形成(1.5和10单位/ml UFH时与对照基质相比分别刺激72%和36%)。用血管内皮生长因子加肿瘤坏死因子α刺激的细胞也得到了类似结果。这些数据证明了肝素对hMVECs增殖的抑制作用,并提供了一种LMWH可能影响肿瘤进展的新机制,即通过使纤维蛋白基质对侵袭的容许性降低来减少微血管结构在其中的向内生长。